BioMérieux: Exor to raise its stake to 8.53% of the capital through a share exchange
The transaction announced on 19 November 2026 is based on a share exchange. Exor will receive BioMérieux shares in exchange for part of its shares in Institut Mérieux, the holding company of the Mérieux family, which remains the majority shareholder with 68.67% of voting rights.
A direct stake increased from 3.87% to 8.53% of the capital
Exor and Institut Mérieux announced on 19 November 2026 a reclassification of shares within the shareholder structure of BioMérieux, a Lyon-based specialist in in vitro diagnostics. The holding company of the Agnelli family is expected to see its direct stake rise from 3.87% to 8.53% of the group's capital.
The transaction takes the form of an exchange. Exor will receive BioMérieux shares as part of a capital reduction of Institut Mérieux, in return for part of the securities it holds in that company. A portion of its indirect exposure, held through the family holding company, will thus become a direct stake in the listed company.
The transaction has not yet been completed. Its completion is expected in December 2026, subject to the expiry of the creditors' opposition period and the formal approval of the shareholders of Institut Mérieux.
Once the exchange is completed, Exor will hold 8.53% of the capital of BioMérieux and 5.35% of its voting rights. The gap between these two percentages is the key point to note: Exor's weight in the capital will remain significantly higher than its weight at general meetings.
Institut Mérieux will retain 55.24% of the capital and 68.67% of the voting rights of BioMérieux. The family holding company thus keeps both the majority of the capital and more than two-thirds of the votes, leaving the balance of control of the company unchanged.
No acting in concert and a board seat proposed for Exor
Exor and the Mérieux family have stated that they do not intend to act in concert with respect to BioMérieux. The two shareholders thus remain independent in their decisions concerning the company, despite the capital ties that bind them.
These ties are maintained at the level of the family holding company. Upon completion of the transaction, Exor will hold 5.02% of the capital of Institut Mérieux and 2.58% of its voting rights. The governance of Institut Mérieux will remain unchanged.
With regard to the governance of BioMérieux, the board of directors is expected to propose, at the next general meeting, the appointment of Benoît Ribadeau-Dumas as Exor's representative. He already sits on the board of directors of Institut Mérieux and holds a censor position, without voting rights, on the board of BioMérieux.
If approved, this appointment would change Exor's representation from an observer role to a director mandate. It accompanies the increase in the direct stake, without changing the position of Institut Mérieux, which remains the reference shareholder in both capital and voting rights.
A relationship begun in 2022, extended to the capital of the subsidiary
Exor has been a shareholder of Institut Mérieux since 2022 and a direct shareholder of BioMérieux since 2025. Its chief executive, John Elkann, stated: “Since 2022, our investment in Institut Mérieux has allowed us to closely observe the entrepreneurial culture of the Mérieux family and its commitment to public health.”
He added that the holding company wishes to support BioMérieux “over the long term”. Exor also holds a portfolio composed mainly of companies in which it is the largest shareholder, including Ferrari, Philips, CNH and Stellantis.
Pierre Boulud, chief executive of BioMérieux, considered that Exor's decision, “less than two years after its first investment in the company”, constitutes “a strong vote of confidence in our strategy, our growth potential and our ability to create value”.
Alexandre Mérieux, chairman of the board of directors of BioMérieux, recalled that as majority shareholder, Institut Mérieux “will continue to support its growth and innovation priorities”. BioMérieux achieved revenue of €4.1 billion in 2025, of which more than 94% outside France.